Filing Analysis
Asset Acquisition
Filed Mar 02, 2026
MEDIUM
Kairos Pharma entered into a binding term sheet to acquire 100% of the worldwide rights to CL-273, a pan EGFR small molecule inhibitor for lung cancer, from Celyn Therapeutics. The transaction involves significant equity issuance and future milestone payments.
Red Flags
- Significant dilution of 16.5% for existing shareholders.
- Substantial future cash/equity obligation of $15 million upon regulatory filing.
- The asset CL-273 is noted as being developed by Eilean Therapeutics, suggesting a potentially complex chain of ownership or licensing with Celyn.
Key Facts
- Acquisition of 100% worldwide rights to CL-273, including IP, manufacturing, and regulatory rights.
- Consideration includes issuing shares representing 16.5% of the Company on a fully diluted basis.
- A $15 million milestone payment is due upon FDA NDA/BLA submission, payable in cash and shares.
- A 2% royalty on U.S. net revenues will be paid for the life of the applicable IP.
- Closing is subject to shareholder approval and potential NYSE American approval.
Asset Acquisition
Filed Feb 26, 2026
MEDIUM
Kairos Pharma, Ltd. has entered into a letter of intent with Celyn Therapeutics, Inc. to acquire worldwide rights to two clinical-stage oncology assets targeting non-small cell lung cancers (NSCLC). The assets include CL-273, a pre-IND pan-EGFR inhibitor, and CL-741, a Phase 1-ready c-MET kinase inhibitor.
Red Flags
- The filing does not disclose the financial terms, purchase price, or potential dilution associated with the acquisition.
- A letter of intent is generally non-binding, and there is no guarantee the transaction will close on the proposed terms.
Key Facts
- Letter of Intent (LOI) signed on February 26, 2026, with Celyn Therapeutics, Inc.
- Acquisition targets worldwide rights to two oncology assets: CL-273 and CL-741.
- CL-273 is described as a pre-IND, reversible, wild-type-sparing pan-EGFR inhibitor.
- CL-741 is described as a Phase 1-ready, orally available type IIb c-MET kinase inhibitor.
- Both assets are specifically designed to target non-small cell lung cancers (NSCLC).
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.